IMNN
Imunon, Inc.3.8800
-0.0900-2.27%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Reaffirms enrollment; details interims.
Q&A largely reaffirmed prepared remarks on OVATION 3's enrollment surge ahead of plan and Phase II's 14.7-month OS edge, with sites averaging above 0.3 patients monthly. No final OVATION 2 data shared with FDA yet—management prioritizes replicating all-comers benefit in Phase III over PARP subgroup hype. Interims set post-2029 enrollment completion, first ~2030. Renewed partnership buzz followed data drop; ex-US sites eyed. On rival frontline threats, execs doubled down on neoadjuvant primacy. No big restructuring savings quantified. Momentum intact—watch funding.
Key Stats
Market Cap
11.91MP/E (TTM)
-Basic EPS (TTM)
-12.53Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Imunon narrowed its Q3 operating loss to $3.5M from $5.0M y/y, while nine-month loss improved to $10.4M from $15.0M, driven by 42% lower R&D spend ($1.9M vs $3.3M) as OVATION 3 ramped with $0.4M costs and PlaCCine Phase 1 wound down. Cash burn slowed; $5.3M cash remains after $9.9M equity raises offset $10.2M operating use—no debt, no FCF disclosed. OVATION program non-clinical costs rose 264%, fueling Phase 3 enrollment at four sites. Diluted EPS loss of $1.16 reconciles to 2.9M shares. Cash won't last twelve months.
8-K
Q3 loss narrows sharply
Imunon reported Q3 2025 net loss of $3.4M, down 29% from $4.8M last year, as R&D expenses dropped 42% to $1.9M amid lower OVATION 2 and PlaCCine costs. Cash stands at $5.3M, funding operations into Q1 2026, while Phase 3 OVATION 3 enrollment exceeds expectations with supportive translational data turning tumors 'hot.' R&D Day drew investigator optimism. Forward-looking statements carry risks.
8-K
Regains Nasdaq compliance
Imunon regained Nasdaq Capital Market compliance with the $1.00 minimum bid price requirement on August 27, 2025, as confirmed by the Hearings Panel, ensuring uninterrupted trading. This stabilizes liquidity amid a recent 15% stock dividend and Phase 3 OVATION 3 trial initiation for IMNN-001 in advanced ovarian cancer. Compliance secured.
10-Q
Q2 FY2025 results
Imunon trimmed Q2 operating expenses 45% y/y to $2.8M, driving net loss down to $2.7M from $4.8M, while H1 losses fell 30% y/y to $6.9M on 45% lower R&D spend—clinical costs dropped 62%, non-clinical 51%. Cash burn slowed to $5.8M YTD operating use (FCF not disclosed in the 10-Q), leaving $4.7M cash at June 30, 2025, bolstered by $4.9M equity raises amid share count doubling to 1.7M. No revenue yet; EPS reconciles to 1.3M weighted shares. Cash won't last. Nasdaq delisting looms.
8-K
Q2 loss shrinks; Phase 3 starts
Imunon reported Q2 net loss of $2.7M, down 43% from $4.8M last year, as R&D costs dropped 57% to $1.2M amid lower trial spending. First patient dosed July 30 in Phase 3 OVATION 3 for IMNN-001 in advanced ovarian cancer; three sites activated, targeting 20 by year-end. Cash at $4.7M funds into Q4. Nasdaq granted listing extension.
ANIX
Anixa Biosciences, Inc.
3.57+0.31
ELTX
Elicio Therapeutics, Inc.
8.15-0.37
IMA
ImageneBio, Inc.
6.25+0.08
IMNM
Immunome, Inc.
23.48+0.84
IMRX
Immuneering Corporation
5.74-0.04
IMVT
Immunovant, Inc.
26.61+0.61
INMB
INmune Bio Inc.
1.89-0.02
IOBT
IO Biotech, Inc.
0.69-0.02
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
REPL
Replimune Group, Inc.
9.61-0.34